Laurus Labs Share Price in Focus: Motilal Oswal Reiterates ‘Buy’ Rating with Rs 1,280 Target Laurus Labs has received a ‘Buy’ rating from Motilal Oswal Financial Services, with the brokerage firm setting a target price of Rs 1,280 for the stock. The recommendation is based on the company’s strong execution and its robust growth trajectory, which has outperformed industry peers. Laurus Labs reported a year-on-year revenue growth of approximately 30% in the first nine months of fiscal year 2026, driven by improved EBITDA margins of around 26%. This margin expansion reflects better operating leverage and a shift toward higher-margin business segments. The brokerage highlighted the company’s expansion in the CDMO (Contract Development and Manufacturing Organisation) and formulation businesses as key growth drivers. These segments have helped mitigate volatility in other parts of the business and contributed to improved profitability. Motilal Oswal noted that Laurus’s strategic investments in capacity creation over the past few years have positioned it to capture opportunities from global innovator clients. The firm expects the company’s new capacities to stabilize and improve utilization, further enhancing margins through operating leverage. Laurus Labs is transitioning toward a more diversified business model, reducing reliance on any single therapy or geographic market. The brokerage anticipates sustained earnings growth in the medium term, fueled by the scaling up of high-value CDMO projects and progress in the formulations business. Motilal Oswal projects that the company will close fiscal year 2026 with a profit after tax (PAT) of Rs 8.5 billion, supported by continued revenue momentum and margin resilience.#motilal_oswal #laurus_labs #cdmo #formulation_business #fiscal_year_2026
